drugset / Trial / NCT00607919

Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

NCT00607919

Phase 4 Completed 209 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)

Timeline

Start
2008-03
Primary completion
2010-11
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 1 mg/kg Oral
Subject Atomoxetine Other / unclassified 1.4 mg/kg Oral